Primary aldosteronism can alter peripheral levels of transforming growth factor β and tumor necrosis factor α

Journal of Endocrinological Investigation

Volumn 32, Issue 9, 2009, Pages 759-765

  Carvajal, C A ^a,b   Herrada, A A ^b,c   Castillo, C R ^a   Contreras, F J ^b,c   Stehr, C B ^a   Mosso, L M ^a   Kalergis, A M ^b,c   Fardella, C E ^a,b  

^a UNIVERSITY OF CHILE   (Chile)

^b Pontificia Universidad Católica de Chile   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Cytokines; Primary aldosteronism; TGF 1

Indexed keywords

ALDOSTERONE; INTERLEUKIN 10; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; ALDOSTERONE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; INTERLEUKIN-10; MALE; MIDDLE AGED; RENIN; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 74949136547     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/6429     Document Type: Article

References (52)

1. Takeda R, Hatakeyama H, Takeda Y, et al. Aldosterone biosynthesis and action in vascular cells. Steroids 1995, 60: 120-4.
2. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008, 51: 161-7.
3. Joffe HV, Adler GK. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 2005, 10: 31-7.
4. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45: 1243-8.
5. Cachofeiro V, Miana M, de Las Heras N, et al. Aldosterone and the vascular system. J Steroid Biochem Mol Biol 2008, 109: 331-5.
6. Gerling IC, Sun Y, Ahokas RA, et al. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol 2003, 285: H813-21.
7. 2 in peripheral blood mononuclear cells. Circulation 2005, 111: 51-7.
8. Casey TM, Mulvey TM, Patnode TA, Dean A, Zakrzewska E, Plaut K. Mammary epithelial cells treated concurrently with TGF-alpha and TGF-beta exhibit enhanced proliferation and death. Exp Biol Med (Maywood) 2007, 232: 1027-40.
9. Wu SP, Theodorescu D, Kerbel RS, et al. TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol 1992, 116: 187-96.
10. Leksa V, Godar S, Schiller HB, et al. TGF-beta-induced apoptosis in endothelial cells mediated by M6P/IGFII-R and mini-plasminogen. J Cell Sci 2005, 118: 4577-86.
11. Sad S, Mosmann TR. Single IL-2-secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine secretion phenotype. J Immunol 1994, 153: 3514-22.
12. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441: 235-8.
13. Nakae S, Komiyama Y, Nambu A, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002, 17: 375-87.
14. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004, 21: 467-76.
15. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203: 2673-82.
16. Tilg H, Moschen A, Kaser A. Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases. Expert Opin Biol Ther 2007, 7: 1051-9.
17. Kasama T, Miwa Y, Isozaki T, Odai T, Adachi M, Kunkel SL. Neutrophil-derived cytokines: potential therapeutic targets in inflammation. Curr Drug Targets Inflamm Allergy 2005, 4: 273-9.
18. Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun 2000, 1: 185-90.
19. Howell WM, Rose-Zerilli MJ. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr 2007, 137: 194S-9S.
20. Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003, 42: 161-5.
21. Fardella CE, Mosso L, Gomez-Sanchez C, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000, 85: 1863-7.
22. Mulatero P, Milan A, Fallo F, et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 2006, 91: 2618-23.
23. Mosso LM, Carvajal CA, Maiz A, et al. A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens 2007, 25: 2125-30.
24. Denolle T, Chatellier G, Julien J, Battaglia C, Luo P, Plouin PF. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. Am J Hypertens 1993, 6: 907-13.
25. Matsumura K, Fujii K, Oniki H, Oka M, Iida M. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens 2006, 19: 13-8.
26. Young WF Jr. Pheochromocytoma and primary aldosteronism: diagnostic approaches. Endocrinol Metab Clin North Am 1997, 26: 801-27.
27. Kreft C, Menard J, Corvol P. Vaule of renin measurement, saralasin test, and acebutolol treatment in hypertension. Kidney Int 1979, 15: 176-83.
28. Kapadia SR, Yakoob K, Nader S, Thomas JD, Mann DL, Griffin BP. Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 2000, 36: 208-12.
29. Fichtlscherer S, Breuer S, Heeschen C, Dimmeler S, Zeiher AM. Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease. J Am Coll Cardiol 2004, 44: 44-9.
30. Torun D, Ozelsancak R, Turan I, Micozkadioglu H, Sezer S, Ozdemir FN. The relationship between obesity and transforming growth factor beta on renal damage in essential hypertension. Int Heart J 2007, 48: 733-41.
31. Zhu S, Liu Y, Wang L, Meng QH. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker. Nephrol Dial Transplant 2008, 23: 2841-6.
32. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008, 29: 367-74.
33. Mutoh A, Isshiki M, Fujita T. Aldosterone enhances ligand-stimulated nitric oxide production in endothelial cells. Hypertens Res 2008, 31: 1811-20.
34. Granger JP, Alberola AM, Salazar FJ, Nakamura T. Control of renal hemodynamics during intrarenal and systemic blockade of nitric oxide synthesis in conscious dogs. J Cardiovasc Pharmacol 1992, 20: S160-2.
35. Ying WZ, Sanders PW. The interrelationship between TGF-beta1 and nitric oxide is altered in salt-sensitive hypertension. Am J Physiol Renal Physiol 2003, 285: F902-8.
36. Mehta JL, Chen HJ, Li DY. Protection of myocytes from hypoxia-reoxygenation injury by nitric oxide is mediated by modulation of transforming growth factor-beta1. Circulation 2002, 105: 2206-11.
37. Ikeuchi M, Tsutsui H, Shiomi T, et al. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 2004, 64: 526-35.
38. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006, 24: 677-88.
39. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007, 8: 950-7.
40. Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-betal controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 2007, 26: 579-91.
41. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007, 8: 942-9.
42. Nakano M, Knowlton AA, Dibbs Z, Mann DL. Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation 1998, 97: 1392-400.
43. Skyschally A, Schulz R, Heusch G. Pathophysiology of myocardial infarction: protection by ischemic pre- and postconditioning. Herz 2008, 33: 88-100.
44. Wong GH, Goeddel DV. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 1988, 242: 941-4.
45. Park HS, Cho SG, Kim CK, et al. Heat shock protein hsp72 is a negative regulator of apoptosis signal-regulating kinase 1. Mol Cell Biol 2002, 22: 7721-30.
46. Kurrelmeyer KM, Michael LH, Baumgarten G, et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A 2000, 97: 5456-61.
47. Hansen PR, Rieneck K, Bendtzen K. Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. Immunol Lett 2004, 91: 87-91.
48. Bendtzen K, Hansen PR, Rieneck K; Spironolactone/Arthritis Study Group. Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol 2003, 134: 151-8.
49. Miura R, Nakamura K, Miura D, et al. Anti-inflammatory effect of spironolactone on human peripheral blood mononuclear cells. J Pharmacol Sci 2006, 101: 256-9.
50. Irita J, Okura T, Manabe S, et al. Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension. Am J Hypertens 2006, 19: 293-7.
51. Takakuwa H, Shimizu K, Izumiya Y, et al. Dietary sodium restriction restores nocturnal reduction of blood pressure in patients with primary aldosteronism. Hypertens Res 2002, 25: 737-42.
52. Williams D, Croat B, Furnace J, et al. The prevalence of a raised aldosterone-renin ratio (ARR) among new referrals to a hypertension clinic. Blood press 2006, 15: 164-8.